Methods used in the selection of instruments for outcomes included in core outcome sets have improved since the publication of the COSMIN/COMET guideline by Gorst, Sarah et al.
Journal of Clinical Epidemiology 125 (2020) 64e75REVIEWARTICLE
Methods used in the selection of instruments for outcomes included in
core outcome sets have improved since the publication of the COSMIN/
COMET guideline
Sarah L. Gorsta,*, Cecilia A.C. Prinsenb, Maximilian Salcher-Konradc, Karen Matvienko-Sikard,
Paula R. Williamsona, Caroline B. Terweeb
aDepartment of Biostatistics, University of Liverpool, Liverpool, UK
bDepartment of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam,
the Netherlands
cDepartment of Health Policy, London School of Economics and Political Science, Cowdray House, London, UK
dSchool of Public Health, University College Cork, Cork, Ireland
Accepted 20 May 2020; Published online 26 May 2020AbstractObjectives: Once a core outcome set (COS) has been defined, it is important to achieve consensus on how these outcomes should be
measured. The aims of this systematic review were to gain insight into the methods used to select outcome measurement instruments and to
determine whether methods have improved following the COnsensus-based Standards for the selection of health Measurement INstruments
(COSMIN)/Core Outcome Measures in Effectiveness Trials (COMET) guideline publication.
Study Design and Setting: Eligible articles, which were identified from the annual COMET systematic review, concerned any COS
development studies that provided a recommendation on how to measure the outcomes included in the COS. Data were extracted on
the methods used to select outcome measurement instruments in accordance with the COSMIN/COMET guideline.
Results: Of the 118 studies included in the review, 48% used more than one source of information when finding outcome measurement
instruments, and 74% performed some form of quality assessment of the measurement instruments. Twenty-three studies recommended one
single instrument for each core outcome included in the COS. Clinical experts and public representatives were involved in selecting instru-
ments in 62% and 28% of studies, respectively.
Conclusion: Methods used to select outcome measurement instruments have improved since the publication of the COSMIN/COMET
guideline. Going forward, COS developers should ensure that recommended outcome measurement instruments have sufficient content val-
idity. In addition, COS developers should recommend one instrument for each core outcome to contribute to the overarching goal of uni-
formity in outcome reporting.  2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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There is lack of consensus with regard to the selection of
outcomes and outcome measurement instruments for clin-
ical trials, which causes inconsistencies in the outcomes re-
ported and difficulties in comparing these outcomes in
systematic reviews and meta-analyses [1]. In addition, there
is great variability in the quality of outcome measurement
instruments used, and it is not always clear if the best in-
strument is being used for a given outcome. To overcome
these issues, standardization of the selection of outcomes
and outcome measurement instruments is needed.ess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 Methods used to select core outcome measurement
instruments vary across studies, with many studies
not meeting the recommended standards.
 Methods used to select outcome measurement in-
struments have improved since the publication of
the COnsensus-based Standards for the selection
of health Measurement INstruments/Core Outcome
Measures in Effectiveness Trials guideline.
What this adds to what was known?
 This is the first study to assess how the outcome
measurement instruments recommended in exist-
ing core outcome sets have been selected and
whether good practices are being followed.
What is the implication and what should change
now?
 Core outcome set developers need to make better
use of the guidance available when agreeing on
how to measure the outcomes included in core
outcome sets.
 Developers need to ensure that outcome measure-
ment instruments are of sufficient quality and espe-
cially have sufficient content validity.
The Core Outcome Measures in Effectiveness Trials
(COMET) Initiative (www.comet-initiative.org), launched
in January 2010, aims to facilitate the development and
application of agreed standardized sets of outcomes, also
known as ‘‘core outcome sets’’ (COSs). A COS is an agreed
minimum set of outcomes that should be measured and re-
ported in all clinical trials of a specific disease or trial pop-
ulation (i.e., what to measure) [1]. Once the COS has been
defined, it is then important to achieve consensus on how
these outcomes should be measured (i.e., how to measure).
The COnsensus-based Standards for the selection of
health Measurement INstruments (COSMIN) initiative
(http://www.cosmin.nl/) aims to improve the selection of
outcome measurement instruments. (When using the term
‘‘outcome measurement instruments,’’ we are referring to
any instruments, definitions, tools, procedures, etc., that
are used to measure an outcome.) In 2016, COSMIN and
COMET published a consensus-based guideline on how
to select outcome measurement instruments for outcomes
included in a COS [2]. Among a large group of interna-
tional stakeholders from 14 different countries, including
clinicians, clinimetricians/psychometricians, epidemiolo-
gists, journal editors, physicians, researchers, and statisti-
cians, consensus was obtained on methods for selectingoutcome measurement instruments for outcomes included
in a COS. COS developers are guided through the process
of instrument selection in four consecutive steps: Step 1,
conceptual considerations; Step 2, finding existing outcome
measurement instruments; Step 3, quality assessment of
outcome measurement instruments; and Step 4, recommen-
dations on the selection of outcome measurement instru-
ments. It is unknown, however, how the outcome
measurement instruments recommended in existing COS
have actually been selected by COS developers and
whether good practices for COS development, as described
in the COSMIN/COMET guideline are being followed.
The aims of this systematic review were to (1) gain
insight into the methods used by COS developers for select-
ing core outcome measurement instruments and (2) deter-
mine whether the methods have improved following the
2016 publication of the COSMIN/COMET guideline. It is
hypothesized that the quality of the methods used to select
the core outcome measurement instruments varies consider-
ably, and it is therefore anticipated that there will be consid-
erable room for improvement in COS development with
regard to instrument selection. However, there are expected
to be improvements in the methods used in studies that
have been published from 2017 onward.2. Methods
2.1. Eligibility criteria
Eligible articles concern COS development studies that
provide recommendations on what and how to measure,
either done together in one study or done in two separate
stages (i.e., two or more studies). We included all COS
studies, identified from the original COMET systematic re-
view and annual updates [3e8], that provided a recommen-
dation on the instruments to measure the outcomes
included in the COS. COS development studies that only pro-
vide a recommendation on what to measure, but do not
consider how to measure, and studies that discuss how to
measure the outcomes but do not give a recommendation
were excluded.
2.2. Literature search
The search strategy for identifying eligible COS devel-
opment studies has been described elsewhere in detail
[3e8]. In brief, a comprehensive search strategy to identify
studies that aimed to define COS in any disease area was
first developed in 2013 [3] (see Appendix A for full search
strategy). Database searches were repeated in 2015 [4],
2016 [5], 2017 [6], 2018 [7], and 2019 [8].
2.3. Data extraction
Four sets of reviewers (C.A.C.P.eS.L.G., S.L.G.eM.S.-
K, M.S.-KeC.A.C.P., and S.L.G.eK.M.-S.) independently
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COS, including the target population, disease area, and the
(number of) outcomes. Data have been extracted in accor-
dance with the COSMIN/COMET guideline (see flowchart
in Appendix B). Methods used to select instruments for the
COS have been extracted, including the approach taken to
identify existing instruments, the evaluation of the quality
and feasibility of instruments, the number of instruments
recommended for use, arguments used for selecting instru-
ments other than quality criteria (measurement properties),
recommendations for additional research on instruments,
and whether any guidance for instrument selection,
including the COSMIN/COMET guideline, was followed
(see Appendix C). To ensure consistency in data extraction,
the data extraction form was pilot tested for a set of five
studies, and the extracted data were compared before ex-
tracting data for the remaining studies. Discrepancies in
data extraction between pairs of reviewers were sought to
be resolved by discussion with the third reviewer, and
consensus was reached.
To improve the quality of our data, first authors of the
included studies were contacted in person by email to
verify the data extracted from their studies, and they were
asked to provide additional information that might be
missing. In case the email could not be delivered, the last
author of that particular study was contacted by email. Ref-
erences of the included papers were also checked to iden-
tify any other relevant articles on instrument selection for
COS.3. Results
A total of 163 articles describing 118 COS development
studies were included in the review. A flow diagram of the
article and abstract selection process is provided in Fig. 1,
guided by Preferred Reporting Items for Systematic Re-
views and Meta-Analyses [9].
Details on COS development studies (e.g., target popu-
lation, disease area) can be found in Appendix D. In sum-
mary, COSs were developed in a variety of geographical
locations, including Asia, Canada, Europe, New Zealand,COS development studies identified 
from the annual COMET review
(n=337)
COS development studies completing 
what and how to measure
(n=118)
Recommendation on what 
to measure only
(n=139)
Consideration of how to 
measure, but no 
recommendation (n=80)
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-
Analyses flowchart of identification of eligible studies from the Core
Outcome Measures in Effectiveness Trials database.South Africa, South America, and the United States. All
COSs were developed in the English language. The number
of core outcomes included in the COS varied between 2
[10,11] and 26 [12]. Following the COMET classifications
[13], COS were developed in 24 different disease areas,
mostly neurology (n 5 19 studies), rheumatology
(n 5 14), heart and circulation (n 5 13), and orthopedics
and trauma (n 5 11). In 36 studies, the COS were devel-
oped for adults; in 17 studies for children and in 20 studies
for both adults and children. In 45 studies (38%), the age
group for which the COS was developed was not specified.
Of the 118 studies, 23 studies reported on core outcomes
for different subgroups of patients, such as age groups
[14e16], acute or chronic conditions [17], disease severity
[18,19], type of study (e.g., prevention trials vs. interven-
tion trials [20,21] or phase IeII vs. phase III clinical trials
[15]); for acute vs. long-term treatment [22] or acute treat-
ment vs. prophylaxis [23e25]; for different diseases/condi-
tions [16,26e32]; or for different settings [33,34].3.1. Methods used in the selection of instruments for
COS
With regard to COS development, 87 of 118 COS
studies used a single process to identify the core outcomes
as well the instruments recommended to measure these out-
comes; whereas 31 studies used a two-stage process that
involved first agreeing on ‘‘what to measure’’ (select core
outcomes) before moving onto the ‘‘how to measure’’
(recommend instruments).3.1.1. Finding existing outcome measurement instruments
It is recommended that COS developers aim for finding
all existing outcome measurement instruments. Multiple
sources of information can be used to find instruments:
(1) performing a systematic review, including a search in
MEDLINE (and EMBASE); (2) use existing review(s);
(3) reference lists; (4) expert opinion; or (5) other sources
of information, such as online databases, book (chapters),
or conference proceedings [2]. Of the 118 included studies,
21 studies (18%) used three or more sources of information
when finding existing outcome measurement instruments,
and 36 studies (30%) used two sources of information.
Sixty-one studies (52%) used only one source of informa-
tion when finding existing outcome measurement instru-
ments, with 39 of 61 studies accessing expert opinion
only. Of the 118 studies, 52 studies (44%) performed a sys-
tematic review; 19 studies (16%) used an existing review;
seven studies (6%) searched reference lists; 49 studies
(42%) accessed expert opinion; and 15 studies (13%) used
other sources of information, mostly instruments used in
clinical trials.
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instruments
COS developers should base their recommendations for
outcome measurement instruments on (1) the quality of the
existing outcome measurement instruments, that is, their
measurement properties (including an evaluation of the
quality of the validation studies), and (2) the feasibility as-
pects of the outcome measurement instruments [2].
3.1.2.1. Measurement properties. It is recommended that
evidence on the measurement properties of outcome mea-
surement instruments should be available in the target pop-
ulation. The quality of instruments is determined in studies
on measurement properties, which should be of high meth-
odological quality. Of the 118 studies, six studies (5%)
[35e40] considered both the results of the measurement
properties of the outcome measurement instruments and
the quality of studies on these measurement properties.
However, in three of these studies [35,36,38], it remains un-
clear whether a best evidence synthesis was performed.
COS developers of 23 of 118 studies (20%) only considered
the results of the measurement properties of the included
outcome measurement instruments but did not consider
the quality of the studies on these measurement properties.
In 58 of 118 studies (49%), COS developers referred to
quality criteria of outcome measurement instruments; how-
ever, there was no mention of any formal assessment of
whether the instruments met these criteria. COS developers
of 31 of 118 studies (26%) did not take the quality of the
outcome measurement instruments into account when mak-
ing their recommendations.
3.1.2.2. Feasibility. Of the 118 studies, 74 studies (63%)
have taken feasibility aspects into consideration in the se-
lection of instruments for the COS, such as availability of
the instrument, cost of an instrument, ease of administra-
tion, and length of an instrument. In 44 studies (37%), there
was no indication that feasibility was taken into consider-
ation in the selection of instruments for the COS.
3.1.3. Recommendations on the selection of outcome
measurement instruments
It is advised to recommend only one outcome measure-
ment instrument for each core outcome per subdomain/sub-
population in the COS, as this will serve the ultimate goal
of standardization of outcome reporting [2]. Of the 118
studies, only 11 studies (9%) recommended one single in-
strument for each core outcome included in the COS
[12,38,39,41e48]. In seven of these 11 studies, one instru-
ment was selected for each core outcome (range: 4e26) in
the COS [12,38,41,43,44,47,48]. In three studies, one in-
strument was recommended for each core outcome or for
each subpopulation (i.e., children and adolescents; range
of core outcomes: 4e10) [42,45,46]. In one study, one in-
strument was recommended for each of the four core out-
comes, with two alternative instruments recommended fortwo of the outcomes because they were free of charge
[39]. In 12 of the 118 studies (10%), one single instrument
was recommended for each core outcome other than those
for which no outcome measurement instrument could be
recommended (range of core outcomes with instrument rec-
ommended: 1e17) [21,37,49e58]. Twelve of the 118
studies (10%) recommended one instrument for all
included core outcomes except one (range included core
outcomes: 3e15) [25,35,40,59e67]. Another seven studies
(6%) recommended multiple instruments for all core out-
comes included in the COS [19,36,68e72]. In 76 of 118
studies (64%), a combination of recommendations was
used in the selection of instruments for each core outcome
included in the COS (i.e., for some outcomes, one instru-
ment was recommended; for some outcomes, multiple in-
struments were recommended, either for the entire group
or for different subgroups; and for some outcomes, no in-
strument was recommended).3.1.4. Consensus procedure used to reach agreement
It is recommended that COS developers use a consensus
procedure to get final agreement on the selected instru-
ments included in the COS [2]. In 80 of 118 studies
(68%), a consensus procedure was used. In 30 of 80 studies,
it was unclear and not specified how consensus was ob-
tained. In 8 of 80 studies, COS developers used a Delphi
technique to reach consensus on the selection of core in-
struments [12,43,48,64,73e76]. Six of the 80 studies were
guided by the Outcome Measures in Rheumatology
(OMERACT) consensus and validation process, which
involved participants voting and then breaking out into
groups to review and discuss domains and instruments
[39,40,63,72,77,78]. In 36 of 80 studies, COS developers
conducted a consensus meeting, including various methods,
to reach consensus on the core instruments. Consensus
methods used at the meetings included presentations, nom-
inal group techniques, group discussions, consensus work-
shops, breakout sessions, and voting. In 38 of 118 studies
(32%), no consensus procedure was used to agree on the in-
struments included in the COS, and recommendations were
formulated by the COS developers.3.1.5. Stakeholders involved in the selection of outcome
measurement instruments
Of the 118 studies, the following stakeholders were
involved in the selection of outcome measurement instru-
ments: clinical experts (n 5 73), nonclinical researchers
(n 5 39), patients and/or public representatives (n 5 33),
regulatory authorities (n 5 20), and industry representa-
tives (n 5 17). An additional 43 studies did not provide
any details about the stakeholders involved in selecting
the outcome measurement instruments. Table 1 displays
the different stakeholder combinations across the 118
studies.
Table 1. Number of studies involving each stakeholder group combination
Stakeholder groups n (%)
Clinical experts 19 (16)
Clinical experts, public representatives,
and nonclinical research experts
11 (9)
Clinical experts and nonclinical research
experts
8 (7)
Clinical experts and public
representatives
7 (6)
Clinical experts, public representatives,
nonclinical research experts, and
industry experts
6 (5)
Clinical experts, public representatives,
nonclinical research experts,
authorities, and industry experts
4 (3)
Clinical experts, public representatives,
nonclinical research experts, and
authorities
3 (3)
Clinical experts, nonclinical research
experts, and authorities
3 (3)
Clinical experts, authorities, and industry
experts
3 (3)
Clinical experts, public representatives,
and authorities
2 (2)
Clinical experts and authorities 2 (2)
Clinical experts and other 2 (2)
Clinical experts, nonclinical research
experts, authorities, and industry
experts
2 (2)
Clinical experts and industry experts 1 (1)
Nonclinical research experts, authorities,
and industry experts
1 (1)
Nonclinical research experts 1 (1)
No details provided 43 (36)
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In 35 of 118 studies (30%), published guidance for instru-
ment selection was used. Most studies (n 5 13) used the
OMERACT guidance [79], whereas other studies used the
Grading of Recommendations, Assessment, and Evaluation
approach [16,80]; Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials recommendations
[81,82];WorldHealthOrganizationeInternational Classifica-
tion of Functioning, Disability andHealth framework [83,84];
European League Against Rheumatism operating procedures
[85]; and InternationalConsortium forHealthOutcomesMea-
surement framework [12,48,64]. Four studies used the COS-
MIN/COMET guideline [39,40,76,84], and a fifth study [37]
used the COSMIN standards for the selection of health status
measurement instruments [86]. Eleven studies
[11,17,32,36,87e93] referred to other guidance, for example,
guidelines from European Crohn’s and Colitis Organisation
guidelines committee; guidance by Physical Rehabilitation
Outcomes Measures, published by the Canadian Physio-
therapy Association; previous work by Hudak et al. [94] orDworkin et al. [95]; other consensus guidelines [96e101];
the Harmonizing Outcome Measures for Eczema (HOME)
roadmap [102]; the framework for the selection of clinical trial
indices proposed byTugwell andBombardier [103]; and guid-
ance from a qualitative evaluation of measures for psychoso-
cial intervention in dementia care. No guidancewas used in 43
of 118 studies (37%), whereas in 40 of 118 studies (34%), it
remains unclear whether any form of guidance was used.
3.1.7. Recommendations for additional research on
instruments
In 55 of 118 studies (47%), recommendations were
made for additional validation studies (n 5 31) or develop-
ment of new instruments (n 5 24).
3.2. Differences between studies published before and
after the publication of the COSMIN/COMET guideline
Of the 118 studies included in this review, 92 studies
(78%) were published before the publication of the
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published after its publication. Table 2 provides a compar-
ison of the methods used in studies published before and af-
ter the publication of the COSMIN/COMET guideline.
Studies published after the publication of the COSMIN/
COMET guideline were more likely to base their recom-
mendations on the quality of the outcome measurement in-
struments, with 8 of 26 studies (31%) considering the
evaluation of the measurement properties of the instruments
and a further 4 of 26 studies (15%) considering both the
quality of the measurement properties of the outcome mea-
surement instruments and the quality of studies on mea-
surement properties. In addition, these studies were also
more likely to comply with the COSMIN/COMET recom-
mendations on the selection of outcome measurement in-
struments, with 11 of 26 studies (42%) recommending
one single instrument for each core outcome included in
the COS, for which a recommendation could be made,
and a further 6 of 26 studies (23%) recommending one in-
strument for all included core outcomes except one. The in-
clusion of stakeholders across all groups increased in the
postguideline studies, with the biggest increase being the
inclusion of patients and/or public representatives, which
increased from 20% to 58%. There was also a 31%
decrease in the number of studies that did not provide
any details about stakeholder involvement. Regarding the
use of guidance, 12 of 26 studies (46%) published
following the COSMIN/COMET guideline used available
guidance for instrument selection, with 5 of 26 studies
(19%) specifically using the COSMIN/COMET guideline
or other COSMIN guidance.4. Discussion
We identified 118 COS development studies that pro-
vided recommendations for how to measure the outcomes
included in a COS. Reviewing these studies has enabled
us to gain insight into the methods used by COS developers
to select outcome measurement instruments. After the pub-
lication of the COSMIN/COMET guideline, there has been
an improvement in the methods used, specifically in rela-
tion to quality assessment, recommendations on the selec-
tion of instruments, stakeholder involvement, and the use
of published guidance.4.1. Finding all existing instruments
COS developers should make better use of the literature
to inform their instrument selection process. Relying solely
on expert opinion to find existing outcome measurement in-
struments, as 33% of studies did in the current review, may
result in only the most commonly used instruments or those
that are favored by clinicians, being considered. To assist
developers in identifying instruments, COSMIN maintains
a database of systematic reviews of outcome measurementinstruments [104]. The ‘‘COSMIN guideline for systematic
reviews of patient-reported outcome measures’’ [105] can
be used for performing a comprehensive literature search
or full systematic review to find all available instruments
if a good-quality systematic review is not available.4.2. Quality assessment of instruments
COS developers should take both the quality of the
studies on measurement properties and the results of the
measurement properties of the outcome measurement in-
struments into account in their recommendations. This will
ensure that the most reliable and valid outcome measure-
ment instruments are selected. However, only 10 of the
COS development studies included in this review consid-
ered both aspects. To assist in the assessment of the quality
of the studies, COSMIN has developed a risk of bias check-
list for use in systematic reviews of patient-reported
outcome measures (PROMs) to assess the risk of bias of
studies on measurement properties [106]. COSMIN has
also proposed quality criteria for measurement properties
of health status questionnaires to assist COS developers
in assessing the quality of identified instruments [106].
In contrast to the assessment of measurement properties,
the feasibility of the identified instruments was generally
taken into consideration in the selection of outcome mea-
surement instruments. We expect that the number of studies
considering these feasibility aspects will continue to remain
high, after the publication of the COSMIN/COMET guide-
line in 2016 [2].4.3. Generic recommendations on the selection of
outcome measurement instruments
COS developers should try to recommend only a single
instrument for each individual outcome included in a COS,
to contribute to the overarching goal of uniformity in
outcome reporting, and to enhance the comparability of
clinical trials. Exceptions can, however, be made for sub-
populations, such as children and adults, and different in-
struments may be necessary for the different age groups.
COS stakeholder groups should include more represen-
tative stakeholders, including patients, when agreeing on
the most appropriate outcome measurement instruments.
Most COS stakeholder groups comprised clinical experts,
whereas public representatives were involved in less than
one-third of studies. This is concerning, as it suggests that
the outcome measures recommended may not be those that
public representatives deem to be most appropriate. Pa-
tients are increasingly being included in selecting the out-
comes for inclusion in COS, with 92% of ongoing COS
development studies in the COMET database planning to
include some degree of patient input [107]. However, pa-
tients and/or public representatives were only included in
the selection of outcome measurement instruments in
28% of COS studies.
Table 2. Methods used in studies published before and after the publication of the COSMIN/COMET guideline
COSMIN/COMET Guideline Task Preguideline, n/N (%) Postguideline, n/N (%)
Finding existing outcome measurement
instruments
Used three or more sources to find
existing outcome measurement
instruments
16/92 (17) 5/26 (19)
Used two sources to find existing
outcome measurement instruments
30/92 (33) 6/26 (23)
Used one source to find existing
outcome measurement instruments
46/92 (50) 15/26 (58)
Quality assessment of outcome
measurement instruments
(a) Measurement properties
Considered both the quality of the
measurement properties of the
outcome measurement
instruments and the quality of
studies on measurement
properties
2/92 (2) 4/26 (15)
Considered the evaluation of the
measurement properties of the
included outcome measurement
instruments
15/92 (16) 8/26 (31)
Referred to quality criteria but no
formal assessment
52/92 (57) 6/26 (23)
Quality of outcome measurement
instruments not taken into account
23/92 (25) 8/26 (31)
(b) Feasibility
Feasibility aspects taken into
consideration
59/92 (64) 15/26 (58)
Recommendations on the selection of
outcome measurement instruments
One single instrument for each core
outcome
3/92 (2) 8/26 (31)
One single instrument for each core
outcome where a recommendation
could be made
9/92 (10) 3/26 (12)
One instrument for all included core
outcomes except one
6/92 (7) 6/26 (23)
Multiple instruments for all core
outcomes
7/92 (8) 0/26 (0)
Combination of recommendations for
each core outcome
67/92 (73) 9/26 (35)
Consensus procedure used to reach
agreement
Used consensus procedure to get final
agreement on the selected
instruments
62/92 (67) 18/26 (69)
Specified details of the consensus
procedure
35/62 (56) 15/18 (83)
Stakeholders involved in the selection of
outcome measurement instruments
Clinical experts 50/92 (54) 23/26(88)
Patients and/or public representatives 18/92 (20) 15/26 (58)
Nonclinical researchers 26/92 (28) 13/26 (50)
Regulatory authorities 15/92 (16) 5/26 (19)
Industry representatives 13/92 (14) 4/26 (15)
(Continued )
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Table 2. Continued
COSMIN/COMET Guideline Task Preguideline, n/N (%) Postguideline, n/N (%)
No details provided about the
stakeholders involved in selecting
the outcome measurement
instruments
40/92 (43) 3/26 (12)
Guidance on instrument selection
Used published guidance 23/92 (25) 12/26 (46)
Recommendations for additional research
on instruments
Made recommendations for the
development of new instruments or
additional validation studies
42/92 (46) 13/26 (50)
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tients in the selection of outcome measurement instruments
than in the selection of the outcomes because the selection
of instruments is mostly based on studies on measurement
properties, which may be difficult for patients to under-
stand. COS developers may need to address additional is-
sues when the population concerned includes people with
cognitive impairment, communication difficulties, or other
vulnerabilities, which make participation in such processes
challenging. Despite the complexities involved in the selec-
tion of outcome measurement instruments, there has been
an increase in the inclusion of patients and/or public repre-
sentatives since the publication of the COSMIN/COMET
guideline. Thus, it is certainly possible to involve patients
and/or public representatives, including those from vulner-
able groups, in this process. However, it should be acknowl-
edged that these groups are likely to need additional
support to participate, and so in some instances, a multi-
stage approach, which allows for adequate support, might
be necessary to ensure that engagement is meaningful.
One potential means of involvement is for patients to judge
the face and content validity (relevance, comprehensive-
ness, and comprehensibility) of the available outcome mea-
surement instruments, which are considered the most
important measurement properties [106,108]. However, it
should be noted that this may not be necessary if previously
published studies have assessed the validity of outcome
measurement instruments with the population in question.4.4. Implications
This review has highlighted that the methods used to
select the core outcome measurement instruments vary
across studies, with many studies not meeting the recom-
mended standards. However, the majority of included
studies were published before the development of the COS-
MIN/COMET guideline, in 2016, and so developers may
have been unaware of methodology for selecting outcome
measurement instruments. There have, however, been clear
improvements in the methods used to select outcome mea-
surement instruments in studies published since the publi-
cation of the COSMIN/COMET guideline. It is unclearwhether such improvements are a direct result of the publi-
cation of the COSMIN/COMET guideline or whether other
variables are responsible for the pre- and post-guideline re-
porting differences. Other potential variables may include
increased COS awareness prompting COS developers to
be more thorough in the outcome measurement instrument
selection process. In addition, the differences in the rate of
inclusion of patients may be attributable to increased public
input in health research in general.
Going forward, we hope that COS developers will use
the COSMIN/COMET guideline, along with the other re-
sources listed previously, to ensure that recommendations
for outcome measurement instruments are developed
using rigorous methodology. A recent paper by Ju et al.
[109] highlights how to apply the COSMIN/COMET
guidance when identifying outcome measurement
instruments.
Apart from the COSMIN/COMET guideline, other
guidelines can also be used to guide the selection of
outcome measurement instruments for COS, for example,
the OMERACT Handbook [110] or HOME roadmap
[102]. Different guidelines put different emphasis on
different steps of the process. For example, in contrast to
the COSMIN/COMET guideline and HOME roadmap,
the OMERACT process does not require a search to find
all available instruments but starts with a selection of in-
struments that seem to have a good match with the target
domain and are considered feasible. Both the COSMIN/
COMET guideline and the OMERACT Handbook address
the need for good content validity of outcome measurement
instruments. Therefore, we suggest that, when resources are
limited, COS developers should evaluate the content valid-
ity of available instruments, if this has not been done pre-
viously, with a small number of patients in their
stakeholder group (e.g., ask patients to evaluate the rele-
vance, comprehensiveness, and comprehensibility of all
items/tests). The COSMIN methodology for assessing con-
tent validity of PROMs can be used for further guidance
[108]. Nevertheless, it should be acknowledged that
although guidelines are important, some flexibility should
be used to best facilitate the participation of patients and/
or public representatives.
72 S.L. Gorst et al. / Journal of Clinical Epidemiology 125 (2020) 64e754.5. Limitations
All the studies included in the current review were identi-
fied from the annual COMET systematic review of COS. We
did not perform a systematic search for all studies relating to
how outcomes should be measured. For example, COS
groups may perform systematic reviews of outcome mea-
surement instruments and select their instruments based on
these reviews but may not publish a separate paper on the se-
lection process for the outcome measurement instruments;
therefore, we cannot be certain that we have identified all
relevant studies. However, we did check the references of
all included papers, and authors of COS studies were con-
tacted to provide additional information.5. Conclusions
In conclusion, COS developers need to make better use
of the guidance available when agreeing on how to measure
the outcomes included in COS. Specifically, developers
need to ensure that outcome measurement instruments are
of sufficient quality and especially have sufficient content
validity. Furthermore, developers should aim to adhere to
uniformity by selecting a single outcome measurement in-
strument for each outcome within a COS.CRediT authorship contribution statement
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